ReviewMolecular diagnosis & therapy2026
Exosomal Cargo-Derived Mediators of Ovarian Cancer Chemoresistance.
Review in Molecular diagnosis & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exosomal miR-148a-3p from LPS-Activated Macrophages Promotes M1 Polarization and Ferroptosis-Related Characteristics of Recipient Macrophages by Reducing SLC7A11.Infection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exosomes are small extracellular vesicles secreted by various cells. They play a vital role in intercellular communication due to their diverse molecular cargo. Recent advancements in biomedical research have enabled a more detailed characterization of exosomes and their significant role in cancer biology, particularly in understanding mechanisms that contribute to chemoresistance. This review focuses on the current understanding of exosomes in ovarian cancer, one of the deadliest gynecological malignancies, known for its high recurrence and treatment failure rates. Chemoresistance in ovarian cancer stems from several factors, including altered drug efflux, enhanced DNA repair mechanisms, changes in the tumor microenvironment, and modifications in signaling pathways. Emerging evidence suggests that exosomes facilitate these processes by transferring regulatory molecules such as proteins, microRNAs (miRNAs), and circular RNAs (circRNAs) between cells, which in turn modulate drug response and tumor progression. For instance, exosomal proteins such as DNA methyltransferase 1 (DNMT1) and circular forkhead box P1 (circFoxp1), along with miRNAs like miR-21-3p, miR-1246, and miR-6836, have been associated with promoting resistance to platinum- and taxane-based chemotherapies. Conversely, some exosomal miRNAs, including miR-30a-5p, may enhance drug sensitivity. Furthermore, circRNAs transported by exosomes, such as hsa_circ_0010467, circ-PIP5K1A, and circ_0025033, play a role in regulating key oncogenic pathways associated with chemoresistance. Overall, these findings highlight the multifaceted role of exosomes in ovarian cancer biology and underscore their potential as both biomarkers and therapeutic targets. A deeper understanding of how exosomes mediate molecular mechanisms may lead to novel strategies for overcoming chemoresistance and improving treatment outcomes for ovarian cancer patients.
Indexed as
Identifiers
41904344What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.